Scan

The latest from the newsletter firehose.

All

Monday, March 23 (Today)

📰
Stanford researchers analyzed 390,000+ messages from 19 people in AI-induced delusional spirals and found chatbots endorsed delusions, claimed sentience, and failed to discourage violence in nearly half of relevant cases.
The Download from MIT Technology Review2h agoRead original →
📰
The key unanswered legal and scientific question is whether chatbots cause delusions or merely amplify pre-existing ones — a distinction that will determine AI company liability in ongoing lawsuits.
The Download from MIT Technology Review2h agoRead original →
📰
The Pentagon is planning to let AI companies train on classified data, a shift from current practice where models answer questions in classified settings but do not learn from that data.
The Download from MIT Technology Review2h agoRead original →

Sunday, March 22 (Yesterday)

📰
MIT Technology Review publishes an annual '10 Breakthrough Technologies' list spotlighting game-changing innovations with major near-term impact.
"Mat Honan, Editor in chief, MIT Technology Review"yesterdayRead original →
📰
35 Innovators Under 35 and 10 Climate Tech Companies to Watch are recurring flagship features tracking people and businesses driving technology change.
"Mat Honan, Editor in chief, MIT Technology Review"yesterdayRead original →
📰
The AI Hype Index is MIT Technology Review's dedicated tracker for the current state of AI, separating signal from noise.
"Mat Honan, Editor in chief, MIT Technology Review"yesterdayRead original →

Friday, March 20

📰
OpenAI revealed plans to build an autonomous AI research intern by September 2025 and a full multi-agent AI researcher system by 2028, calling it the company's new 'north star'.
The Download from MIT Technology Review3d agoRead original →
📰
Kalshi raised $1 billion at a $22 billion valuation—double its December valuation—even as Arizona's AG charges the prediction market platform with 'illegal gambling'.
The Download from MIT Technology Review3d agoRead original →
📰
Two new clinical studies on psychedelic drugs like psilocybin underscore persistent methodological challenges, with MIT Tech Review's author arguing these substances have been significantly overhyped.
The Download from MIT Technology Review3d agoRead original →